2025-01-012025-12-312025-12-31false03679174MARKS TEY PHARMACY LIMITED2026-09-03falseiso4217:GBPxbrli:pure036791742024-12-31036791742025-12-31036791742025-01-012025-12-31036791742023-12-31036791742024-12-31036791742024-01-012024-12-3103679174bus:SmallEntities2025-01-012025-12-3103679174bus:AuditExempt-NoAccountantsReport2025-01-012025-12-3103679174bus:FullAccounts2025-01-012025-12-3103679174bus:PrivateLimitedCompanyLtd2025-01-012025-12-3103679174core:WithinOneYear2025-12-3103679174core:AfterOneYear2025-12-3103679174core:WithinOneYear2024-12-3103679174core:AfterOneYear2024-12-3103679174core:ShareCapital2025-12-3103679174core:SharePremium2025-12-3103679174core:RevaluationReserve2025-12-3103679174core:OtherReservesSubtotal2025-12-3103679174core:RetainedEarningsAccumulatedLosses2025-12-3103679174core:ShareCapital2024-12-3103679174core:SharePremium2024-12-3103679174core:RevaluationReserve2024-12-3103679174core:OtherReservesSubtotal2024-12-3103679174core:RetainedEarningsAccumulatedLosses2024-12-3103679174core:LandBuildings2025-12-3103679174core:PlantMachinery2025-12-3103679174core:Vehicles2025-12-3103679174core:FurnitureFittings2025-12-3103679174core:OfficeEquipment2025-12-3103679174core:NetGoodwill2025-12-3103679174core:IntangibleAssetsOtherThanGoodwill2025-12-3103679174core:ListedExchangeTraded2025-12-3103679174core:UnlistedNon-exchangeTraded2025-12-3103679174core:LandBuildings2024-12-3103679174core:PlantMachinery2024-12-3103679174core:Vehicles2024-12-3103679174core:FurnitureFittings2024-12-3103679174core:OfficeEquipment2024-12-3103679174core:NetGoodwill2024-12-3103679174core:IntangibleAssetsOtherThanGoodwill2024-12-3103679174core:ListedExchangeTraded2024-12-3103679174core:UnlistedNon-exchangeTraded2024-12-3103679174core:LandBuildings2025-01-012025-12-3103679174core:PlantMachinery2025-01-012025-12-3103679174core:Vehicles2025-01-012025-12-3103679174core:FurnitureFittings2025-01-012025-12-3103679174core:OfficeEquipment2025-01-012025-12-3103679174core:NetGoodwill2025-01-012025-12-3103679174core:IntangibleAssetsOtherThanGoodwill2025-01-012025-12-3103679174core:ListedExchangeTraded2025-01-012025-12-3103679174core:UnlistedNon-exchangeTraded2025-01-012025-12-3103679174core:MoreThanFiveYears2025-01-012025-12-3103679174core:Non-currentFinancialInstruments2025-12-3103679174core:Non-currentFinancialInstruments2024-12-3103679174dpl:CostSales2025-01-012025-12-3103679174dpl:DistributionCosts2025-01-012025-12-3103679174core:LandBuildings2025-01-012025-12-3103679174core:PlantMachinery2025-01-012025-12-3103679174core:Vehicles2025-01-012025-12-3103679174core:FurnitureFittings2025-01-012025-12-3103679174core:OfficeEquipment2025-01-012025-12-3103679174dpl:AdministrativeExpenses2025-01-012025-12-3103679174core:NetGoodwill2025-01-012025-12-3103679174core:IntangibleAssetsOtherThanGoodwill2025-01-012025-12-3103679174dpl:GroupUndertakings2025-01-012025-12-3103679174dpl:ParticipatingInterests2025-01-012025-12-3103679174dpl:GroupUndertakingscore:ListedExchangeTraded2025-01-012025-12-3103679174core:ListedExchangeTraded2025-01-012025-12-3103679174dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2025-01-012025-12-3103679174core:UnlistedNon-exchangeTraded2025-01-012025-12-3103679174dpl:CostSales2024-01-012024-12-3103679174dpl:DistributionCosts2024-01-012024-12-3103679174core:LandBuildings2024-01-012024-12-3103679174core:PlantMachinery2024-01-012024-12-3103679174core:Vehicles2024-01-012024-12-3103679174core:FurnitureFittings2024-01-012024-12-3103679174core:OfficeEquipment2024-01-012024-12-3103679174dpl:AdministrativeExpenses2024-01-012024-12-3103679174core:NetGoodwill2024-01-012024-12-3103679174core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3103679174dpl:GroupUndertakings2024-01-012024-12-3103679174dpl:ParticipatingInterests2024-01-012024-12-3103679174dpl:GroupUndertakingscore:ListedExchangeTraded2024-01-012024-12-3103679174core:ListedExchangeTraded2024-01-012024-12-3103679174dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-01-012024-12-3103679174core:UnlistedNon-exchangeTraded2024-01-012024-12-3103679174core:NetGoodwill2025-12-3103679174core:IntangibleAssetsOtherThanGoodwill2025-12-3103679174core:LandBuildings2025-12-3103679174core:PlantMachinery2025-12-3103679174core:Vehicles2025-12-3103679174core:FurnitureFittings2025-12-3103679174core:OfficeEquipment2025-12-3103679174core:AfterOneYear2025-12-3103679174core:WithinOneYear2025-12-3103679174core:ListedExchangeTraded2025-12-3103679174core:UnlistedNon-exchangeTraded2025-12-3103679174core:ShareCapital2025-12-3103679174core:SharePremium2025-12-3103679174core:RevaluationReserve2025-12-3103679174core:OtherReservesSubtotal2025-12-3103679174core:RetainedEarningsAccumulatedLosses2025-12-3103679174core:NetGoodwill2024-12-3103679174core:IntangibleAssetsOtherThanGoodwill2024-12-3103679174core:LandBuildings2024-12-3103679174core:PlantMachinery2024-12-3103679174core:Vehicles2024-12-3103679174core:FurnitureFittings2024-12-3103679174core:OfficeEquipment2024-12-3103679174core:AfterOneYear2024-12-3103679174core:WithinOneYear2024-12-3103679174core:ListedExchangeTraded2024-12-3103679174core:UnlistedNon-exchangeTraded2024-12-3103679174core:ShareCapital2024-12-3103679174core:SharePremium2024-12-3103679174core:RevaluationReserve2024-12-3103679174core:OtherReservesSubtotal2024-12-3103679174core:RetainedEarningsAccumulatedLosses2024-12-3103679174core:NetGoodwill2023-12-3103679174core:IntangibleAssetsOtherThanGoodwill2023-12-3103679174core:LandBuildings2023-12-3103679174core:PlantMachinery2023-12-3103679174core:Vehicles2023-12-3103679174core:FurnitureFittings2023-12-3103679174core:OfficeEquipment2023-12-3103679174core:AfterOneYear2023-12-3103679174core:WithinOneYear2023-12-3103679174core:ListedExchangeTraded2023-12-3103679174core:UnlistedNon-exchangeTraded2023-12-3103679174core:ShareCapital2023-12-3103679174core:SharePremium2023-12-3103679174core:RevaluationReserve2023-12-3103679174core:OtherReservesSubtotal2023-12-3103679174core:RetainedEarningsAccumulatedLosses2023-12-3103679174core:AfterOneYear2025-01-012025-12-3103679174core:WithinOneYear2025-01-012025-12-3103679174core:Non-currentFinancialInstrumentscore:CostValuation2025-01-012025-12-3103679174core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-01-012025-12-3103679174core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-01-012025-12-3103679174core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-01-012025-12-3103679174core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-01-012025-12-3103679174core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-01-012025-12-3103679174core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-01-012025-12-3103679174core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-01-012025-12-3103679174core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-01-012025-12-3103679174core:Non-currentFinancialInstrumentscore:CostValuation2025-12-3103679174core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-12-3103679174core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-12-3103679174core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-12-3103679174core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-12-3103679174core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-12-3103679174core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-12-3103679174core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-12-3103679174core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-12-3103679174core:Non-currentFinancialInstrumentscore:CostValuation2024-12-3103679174core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-12-3103679174core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-12-3103679174core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-12-3103679174core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-12-3103679174core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-12-3103679174core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-12-3103679174core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-12-3103679174core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-12-3103679174bus:Director12025-01-012025-12-3103679174core:FurnitureFittingsToolsEquipment2024-12-3103679174core:FurnitureFittingsToolsEquipment2025-01-012025-12-3103679174core:FurnitureFittingsToolsEquipment2025-12-31

MARKS TEY PHARMACY LIMITED

Registered Number
03679174
(England and Wales)

Unaudited Financial Statements for the Year ended
31 December 2025

MARKS TEY PHARMACY LIMITED
Company Information
for the year from 1 January 2025 to 31 December 2025

Director

OSORIO RODRIGUEZ, Jose

Registered Address

89 London Road
Marks Tey
Colchester
CO6 1EB

Registered Number

03679174 (England and Wales)
MARKS TEY PHARMACY LIMITED
Balance Sheet as at
31 December 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Tangible assets35,6085,688
5,6085,688
Current assets
Stocks432,50033,250
Debtors5617,367513,883
Cash at bank and on hand379,932240,584
1,029,799787,717
Creditors amounts falling due within one year6(401,413)(352,110)
Net current assets (liabilities)628,386435,607
Total assets less current liabilities633,994441,295
Net assets633,994441,295
Capital and reserves
Called up share capital500500
Share premium19,80019,800
Profit and loss account613,694420,995
Shareholders' funds633,994441,295
The financial statements were approved and authorised for issue by the Director on 3 September 2026, and are signed on its behalf by:
OSORIO RODRIGUEZ, Jose
Director
Registered Company No. 03679174
MARKS TEY PHARMACY LIMITED
Notes to the Financial Statements
for the year ended 31 December 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.
Revenue from sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Employee benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Reducing balance (%)
Office Equipment25
Finance leases and hire purchase contracts
Assets held under finance leases which are leases where substantially all the risks and rewards of ownership of the asset have passed to the company, and hire purchase contracts are capitalised in the balance sheet. They are depreciated over the shorter of their useful lives or the term of the lease.
Stocks and work in progress
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.
2.Average number of employees

20252024
Average number of employees during the year1213
3.Tangible fixed assets

Land & buildings

Plant & machinery

Fixtures & fittings

Office Equipment

Total

£££££
Cost or valuation
At 01 January 25114,93029,118107,87212,645264,565
Additions---2,1242,124
At 31 December 25114,93029,118107,87214,769266,689
Depreciation and impairment
At 01 January 25114,93029,118107,8726,957258,877
Charge for year---2,2042,204
At 31 December 25114,93029,118107,8729,161261,081
Net book value
At 31 December 25---5,6085,608
At 31 December 24---5,6885,688
4.Stocks

2025

2024

££
Finished goods32,50033,250
Total32,50033,250
5.Debtors: amounts due within one year

2025

2024

££
Trade debtors / trade receivables289,605278,720
Amounts owed by group undertakings290,577199,676
Other debtors31,64530,401
Prepayments and accrued income5,5405,086
Total617,367513,883
6.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables189,484175,039
Taxation and social security72,23947,158
Payments received on account134,433126,856
Other creditors5,1622,849
Accrued liabilities and deferred income95208
Total401,413352,110
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
7.Related party transactions
At the yearend, the company was owed £290,577 (2024: £199,676) by Marks Tey Healthcare Ltd. The companies are related as Marks Tey Healthcare Ltd owns 100% share capital of Marks Tey Pharmacy Ltd.